Andere talen ToolGen Incorporated

Aandelen

A199800

KR7199800004

slotkoers Korea S.E. Andere beurzen 00:00:00 26-04-2024			Variatie 5 dagen	Verschil t.o.v. 1 jan (%)
67.100 ^KRW	-0,59%		+9,82%	-4,42%

2023	Toolgen leidt de ontwikkeling van talrijke baanbrekende genoombewerkingstechnieken	CI
2023	ToolGen Incorporated meldt winstresultaten voor het gehele jaar eindigend op 31 december 2022	CI

Andere talen

Krijg toegang tot al het nieuws over alle bedrijven: mis nooit meer een winstgevende beleggingskans!

Gratis inschrijven

The 2023 Pharmaceutical Patent Review	17/04
DCC Insights Issue 19	16/11
ToolGen Incorporated announced that it has received KRW 33 billion in funding	02/11
ToolGen Incorporated announced that it expects to receive KRW 33 billion in funding	31-10-23
ToolGen Incorporated v Fisher (No 2) – Lessons In Entitlement To Priority From The Australian Federal Court	15-08-23
Toolgen Leads Development of Numerous Cutting-Edge Genome Editing Techniques	18-04-23
ToolGen Incorporated Reports Earnings Results for the Full Year Ended December 31, 2022	23-03-23
ToolGen Incorporated(KOSDAQ:A199800) added to S&P Global BMI Index	19-09-22
MCureX Therapeutics, Inc. Signs Contract for Joint Research with Toolgen, Inc	15-06-22
ToolGen Incorporated has completed an IPO in the amount of KRW 70 billion.	06-12-21
ToolGen Incorporated has filed an IPO.	14-09-21
ToolGen Incorporated announced that it has received KRW 10.0000004 billion in funding from Genexine, Inc.	21-12-20
ToolGen Incorporated announced that it expects to receive KRW 10.0000004 billion in funding from Genexine, Inc.	11-12-20
Genexine, Inc. cancelled the acquisition of ToolGen Incorporated.	20-08-19
Genexine, Inc. agreed to acquire ToolGen Incorporated for approximately KRW 350 billion.	19-06-19
ToolGen, Inc., Demonstrates CRISPR/Cas9 Gene Editing Improves Anti-Tumor Activity of Human Car-T Cells	17-05-18
Monsanto Company and ToolGen, Inc. Announce Global Licensing Agreement on CRISPR Platform, Underscore the Benefits of Innovation for Farmers	18-08-17
ToolGen, Inc. Highlights Study Results Demonstrating Utility of AAV-Compatible Cas9 System in vivo Genome Editing	22-02-17
ToolGen Incorporated announced that it has received KRW 10.0223744 billion in funding	14-10-16
ToolGen Incorporated announced that it expects to receive KRW 10.0223744 billion in funding	13-10-16

Geen resultaten voor deze zoekopdracht

Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Andere talen ToolGen Incorporated

Aandelen

A199800

KR7199800004

Andere talen

Filters